 Neuronetics Inc NASDAQ: STIM reported Q2 EPS loss of 0.29 lower than 0.41 posted a year ago, but missing the consensus of 0.24. Revenue of 14.2 million, missed the consensus of 14.72 million, increased 46 YY primarily due to increased U.S. treatment session revenue. 